Log in

NASDAQ:DTILPrecision BioSciences Stock Price, Forecast & News

$5.67
+1.01 (+21.67 %)
(As of 04/7/2020 08:40 AM ET)
Add
Compare
Today's Range
$4.78
Now: $5.67
$5.99
50-Day Range
$4.66
MA: $6.83
$8.28
52-Week Range
$4.60
Now: $5.67
$23.67
Volume655,099 shs
Average Volume437,009 shs
Market Capitalization$291.55 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DTIL
CUSIPN/A
CIKN/A
Phone919-314-5512

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.24 million
Book Value$2.72 per share

Profitability

Net Income$-92,880,000.00
Net Margins-417.65%

Miscellaneous

Employees127
Market Cap$291.55 million
Next Earnings Date5/4/2020 (Estimated)
OptionableNot Optionable

Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.


Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

How has Precision BioSciences' stock been impacted by COVID-19 (Coronavirus)?

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DTIL shares have decreased by 12.6% and is now trading at $5.67. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Precision BioSciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Precision BioSciences.

When is Precision BioSciences' next earnings date?

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Precision BioSciences.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences Inc (NASDAQ:DTIL) announced its quarterly earnings data on Tuesday, March, 10th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.15. The firm had revenue of $6.52 million for the quarter, compared to analysts' expectations of $9.56 million. Precision BioSciences had a negative net margin of 417.65% and a negative return on equity of 66.96%. View Precision BioSciences' earnings history.

What price target have analysts set for DTIL?

8 brokerages have issued 1 year price targets for Precision BioSciences' shares. Their forecasts range from $19.00 to $24.00. On average, they anticipate Precision BioSciences' stock price to reach $22.17 in the next year. This suggests a possible upside of 290.9% from the stock's current price. View analysts' price targets for Precision BioSciences.

What are Wall Street analysts saying about Precision BioSciences stock?

Here are some recent quotes from research analysts about Precision BioSciences stock:
  • 1. According to Zacks Investment Research, "Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina. " (1/14/2020)
  • 2. HC Wainwright analysts commented, "Our $21 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our 13-year DCF model. Our DCF is based on: beta of 1.6, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.5%, and tax rate of 15% beginning in FY 2028. Our $21 price target remains leveraged on the outcome of for which we assign a 25% and 10% POS, respectively, given their IND-ready status. These two assets represent approximately 73% of our rNPV, i.e., $15 per share." (7/16/2019)

Has Precision BioSciences been receiving favorable news coverage?

Headlines about DTIL stock have been trending very negative this week, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Precision BioSciences earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutPrecision BioSciences.

Are investors shorting Precision BioSciences?

Precision BioSciences saw a increase in short interest in March. As of March 13th, there was short interest totaling 1,957,900 shares, an increase of 18.7% from the February 27th total of 1,650,000 shares. Based on an average daily trading volume, of 519,100 shares, the short-interest ratio is presently 3.8 days. Currently, 5.8% of the shares of the company are sold short. View Precision BioSciences' Current Options Chain.

Who are some of Precision BioSciences' key competitors?

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Exxon Mobil (XOM), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Alector (ALEC), Flexion Therapeutics (FLXN), Gilead Sciences (GILD), Gossamer Bio (GOSS), Immunomedics (IMMU) and NVIDIA (NVDA).

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the following people:
  • Mr. Matthew R. Kane, Co-Founder, CEO, Pres & Director (Age 42)
  • Dr. Derek Jantz Ph.D., Co-founder, Chief Scientific Officer & Director (Age 43)
  • Dr. Jefferson J. Smith Ph.D., Co-Founder & CTO
  • Mr. Abid Ansari, Chief Financial Officer (Age 41)
  • Ms. Molly Lukes PHR, SHRM-CP, Director of HR

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $5.67.

How big of a company is Precision BioSciences?

Precision BioSciences has a market capitalization of $291.55 million and generates $22.24 million in revenue each year. The company earns $-92,880,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Precision BioSciences employs 127 workers across the globe. View additional information about Precision BioSciences.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is http://www.precisionbiosciences.com/.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at 919-314-5512 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel